What is imaware?
Imaware operates a sophisticated diagnostics platform that bridges the gap between clinical-grade testing and personalized wellness management. The company provides a comprehensive suite of services tailored for diverse stakeholders, including health systems, pharmaceutical entities, and corporate employers. By integrating customizable at-home testing solutions with data-driven health insights, the platform enables organizations to deploy highly effective corporate wellness initiatives. The core value proposition lies in its ability to streamline complex diagnostic operations while delivering actionable, biomarker-based recommendations. This approach not only enhances individual health outcomes but also fosters deeper engagement between health providers and their user bases, establishing imaware as a foundational player in the digital health transformation.
How much funding has imaware raised?
imaware has raised a total of $15M across 1 funding round:
Angel/Seed
$15M
Angel/Seed (2022): $15M with participation from June Fund, Lucas von Cranach, Naren Shaam, Christian Reber, Cherry Ventures, and Lakestar
Key Investors in imaware
June Fund
June Fund is a global technology investor focused on new paradigms across all stages, supporting infrastructure and open software platforms with a long-term, intellectual approach.
Cherry Ventures
Cherry Ventures is a Berlin-based venture capital firm founded by former entrepreneurs that provides early-stage capital and operational expertise to European startups across various sectors.
Lakestar
Lakestar is a prominent venture capital firm that partners with visionary entrepreneurs in Deep Tech, Healthcare, and Fintech, offering support from Seed to Growth stages.
What's next for imaware?
With this major strategic investment, imaware is poised to scale its operational footprint and deepen its penetration into the enterprise health market. The company's roadmap likely involves expanding its biomarker testing portfolio and enhancing its proprietary data analytics engine to support more complex health management programs. As the demand for decentralized, patient-centric diagnostics continues to rise, imaware is well-positioned to capitalize on the shift toward proactive, data-informed healthcare. Future growth will likely focus on strengthening partnerships with large-scale payors and health systems, ensuring that their diagnostic infrastructure becomes a standard component of modern corporate and clinical wellness strategies. The firm's ability to maintain high-quality, scalable testing solutions will be the primary driver of its long-term competitive advantage in the global health-tech sector.
See full imaware company page
